• Seaport Therapeutics began dosing patients in a Phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance.
• Topline results have not been presented; data are expected in early 2028.
• Study aims to show clinical activity on sleep and anxiety symptoms, supporting the case for later-stage development.
• Earlier Phase 1 findings were presented previously, showing improved drug exposure versus standard agomelatine with no liver-safety signals.
• Seaport plans to start a global Phase 2/3 trial in the first half of 2027, with topline results targeted by end-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seaport Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610070700BIZWIRE_USPR_____20261007_BW823670) on October 07, 2026, and is solely responsible for the information contained therein.